The small number of ETV4 subtypes among prostate patients and the short history of research on ETV4 rearrangement have limited understanding of the molecular features of ETV4 subtypes of prostate cancer and, in turn, have resulted in an absence of effective targeted therapy for these patients. Here, ETV4 is linked to prostate carcinoma.